Browse Studies — Arctuva

Phase 1

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 1

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tum…

Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more

Estimated

~$10 – $8,750

Phase 2

TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT)

This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/horm…

Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer+2 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07340541

Phase 2

ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen…

Male Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Negative Breast Carcinoma

Estimated

~$10 – $7,500

Jose Pablo LeoneNCT05501704